EP0530861A2 - Topical antimicrobial pharmaceutical compositions - Google Patents

Topical antimicrobial pharmaceutical compositions Download PDF

Info

Publication number
EP0530861A2
EP0530861A2 EP92119054A EP92119054A EP0530861A2 EP 0530861 A2 EP0530861 A2 EP 0530861A2 EP 92119054 A EP92119054 A EP 92119054A EP 92119054 A EP92119054 A EP 92119054A EP 0530861 A2 EP0530861 A2 EP 0530861A2
Authority
EP
European Patent Office
Prior art keywords
fatty acid
composition according
pharmaceutical composition
topical antimicrobial
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP92119054A
Other languages
German (de)
French (fr)
Other versions
EP0530861B1 (en
EP0530861A3 (en
Inventor
Jon Joseph Kabara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0530861A2 publication Critical patent/EP0530861A2/en
Publication of EP0530861A3 publication Critical patent/EP0530861A3/en
Application granted granted Critical
Publication of EP0530861B1 publication Critical patent/EP0530861B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/12Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group, wherein Cn means a carbon skeleton not containing a ring; Thio analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Definitions

  • the present invention relates generally to topical pharmaceutical compositions and, more particularly, to primarily aqueous solutions exhibiting unique antimicrobial properties.
  • antimicrobial agents plays an important part in current medical therapy. This is particularly true in dermatology, where the most effective course of treatment for skin, mucous membranes, hair lesions, or infections frequently includes the use of a topical antimicrobial agent.
  • the present invention includes topical compositions and methods which provide unique performance against a broad spectrum of microbes with excellent speed.
  • carboxylic acids are known to be good antimicrobial agents. However, when these acidic solutions are directly applied to an animal's skin, they may interfere with wound healing, cause irritation, inflammation or the like. Also, these solutions have poor solubility properties in water which, in turn, limits the efficacy of aqueous solutions employing these materials.
  • United States Patent No. 4,406,884 issued to Fawzi discloses a topical antimicrobial composition in the form of an aqueous gel or lotion. This composition contains C5-C12 fatty acids and has a pH no greater than about 5.
  • United States Patent No. 4,343,798 issued to Fawzi teaches a topical antimicrobial anti-inflammatory composition having a pH less than about 5 and containing C5-C12 fatty acids together with a corticosteroid component.
  • United States Patent No. 4,489,097 issued to Stone teaches the addition of anti-fungal/antibacterial materials to sterile compositions.
  • the antifungal/antibacterial material disclosed is a C4-C9 carboxylate antimicrobial agent having a pH of about 6.0 or below.
  • United States Patent No. 4,410,442 issued to Lucas, et al. teaches solutions for use with hydrophilic soft contact lenses containing C5-C12 fatty acids, especially octanoic acid.
  • United States Patent No. 4,392,848 issued to Lucas, et al. teaches a catheter having a liquid reservoir of an antimicrobial agent flowing through the lumen of the catheter.
  • the antimicrobial agent disclosed is a straight-chain carboxylic acid or carboxylic acid salt having a C4-C9 chain.
  • the antimicrobial being a C3-C12 alkane, alkene or alkyne monocarboxylate.
  • United States Patent Nos. 4,343,788 and 4,479,795, both issued to Mustacich, et al. teach medical polymers that provide diffusion for certain carboxylate antimicrobial agents.
  • United States Patent No. 4,002,775 issued to Kabara teaches a food grade microbicidal composition having a monoester with a C12 aliphatic fatty acid as its primary microbicide.
  • United States Patent No. 1,772,975 issued to Weiland teaches the use of lactic acid, acetic acid, or combinations thereof, as antiseptics at properly adjusted pH levels.
  • United States Patent No. 2,154,449 issued to Hoffman et al. teaches the use of aliphatic C3-C12 carboxylic acids and their salts as mold inhibitors in food compositions.
  • United States Patent No. 2,190,714 issued to Hoffman, et al. teaches the addition of a C3-C12 carboxylic acid to inhibit growth food products other than margarine and sourdough bread.
  • United States Patent No. 3,404,987 to Kooistra, et al. teaches an antimicrobial containing edible mineral salt and edible acid preservative substances, particularly propionic acid.
  • United States Patent No. 2,729,586 issued to Peck teaches a therapeutic compositions having at least one salt of a C3-C11 monocarboxylic acid and water soluble chlorophyll.
  • Kabara, J., Antimicrobial Agents Derives from Fatty Acids , JAOCS, Vol. 61, No. 2, Pgs. 397-403 (1984) teaches the use of saturated and unsaturated fatty acids as antimicrobial agents.
  • Kabara, J., GRAS Antimicrobia Agents for Cosmetic Products Journal of the Society of Cosmetic Chemists, Vol. 31, Pgs.
  • Nonionic Surfactants Schick, M.J., Marcel Dekker, Inc., New York (1966) and Dillan, K., Effects of the Ethylene Oxide Distribution on Nonionic Surfactant Properties , JAOCS, Vol. 62, No. 7, Pgs. 1144-1151 (1985) teach the ethoxylation of primary alcohols to product nonionic surfactants.
  • the present invention relates to preservative pharmaceutical compositions and methods, especially those useful when applied topically and/or those which exhibit good shelf stability.
  • the present invention relates to the discovery that the overall antimicrobial efficacy and pharmaceutical acceptability of certain glycerol fatty acid esters can be dramatically increased by either (1) the addition of certain ether groups, particularly ethoxy and propoxy units; (2) by use in combination with select fatty acid materials, (3) a combination of (1) and (2).
  • Such modified glycerol fatty acid ester materials retain or exhibit an improved overall spectrum and speed of activity while producing fewer or reduced (in severity) side effects.
  • Such a material is especially useful when compared to the unmodified material in that it produces much less irritation at the site of application.
  • the present invention further relates to the discovery that the spectrum and speed of activity of both modified and unmodified fatty acid esters can be significantly improved when used in a tertiary mixture or in combination with a mixture of two or more C6-C18 fatty acids, preferably C6-C12 fatty acids. All these materials are in turn employed in combination with a topical carrier. Such materials provide effective topical antimicrobial activity and are accordingly useful in the treatment and prevention of conditions which are caused, or aggravated by microbial organisms (including viruses) on skin and mucous membranes or are otherwise relates to microbes.
  • compositions of the present invention exhibit exceptional preservative applications.
  • the present compositions provide outstanding preservative characteristics when added primarily as a preservative in food stuffs, cosmetic formulations and pharmaceutical compositions (topical; parenteral; intramuscular; and intravenous).
  • the preservative applications are further discussed in my copending patent application entitled “ANTIMICROBIAL PRESERVATIVE COMPOSITIONS", filed on the same day as the present application.
  • compositions are useful in veterinary applications as a teat dip, an eye medication and an ear medication.
  • the glyceryl fatty acid ester which is to be ethoxylated or propoxylated for use in the compositions and methods of the present invention is preferably selected from the group consisting of polyhydric alcohols, polyglycerols, sucrose, glucose, sorbitol, propylenediol and glyceryl fatty acid esters having about six to about twenty-one carbon atoms.
  • Such preferred compounds include monocaprylin, monocaprin, monolaurin, monomyristin, monopalmitolein, ⁇ -monopalmitin, monostearin, monoolein, 1-monolinolein, 1-monolinolenin, and mixtures thereof.
  • monocaprylin monocaprin, monolaurin, monomyristin, monopalmitolein, monoolein, monoicosenin and monoerucin and mixtures thereof.
  • the highly preferred compounds include monocaprylin, monocaprin and monolaurin and mixtures thereof.
  • Monolaurin is most highly preferred taking into account cost, availability and activity.
  • the glyceryl fatty acid esters are ethoxylated or propoxylated by conventional ethoxylating or propoxylating compounds and techniques.
  • the compounds are preferably selected from the group consisting of ethylene oxide, propylene oxide, and mixtures thereof, and similar ringed compounds which provide a material which is effective.
  • the ethoxylation compound is selected from the group consisting of ethylene oxide, propylene oxide and mixtures thereof.
  • the glyceryl fatty acid esters are ethoxylated or propoxylated under controlled conditions preferably within a narrow range according to conventional methods, such as those in the Dillan article further incorporated by reference.
  • the glyceryl fatty acid esters are ethoxylated or propoxylated by a suitable amount of ethoxylate or propoxylate compound.
  • the ethoxylation or propoxylation compound is reacted at a level of about 0.25 to about 25, more preferably about 0.5 to about 20 moles, more preferably, at about 0.5 to about 3.0 moles and, still more preferably, at about 0.5 to about 1.0 moles of ethoxylate or propoxylate per mole of glyceryl ester.
  • the resulting products useful in the compositions and methods of the present invention generally contain at least about 1 mole of ethoxylate or propoxylate per four moles of glyceryl ester; in other words there is at least about one-quarter, and preferably at least about one-half, ether unit or moiety per glyceryl fatty acid ester unit or molecule.
  • This could be further expressed as stating that useful ethoxylated glyceryl fatty acid esters of the present invention are esters wherein at least one-quarter, and preferably at least one-half of the total glyceryl ester has reunited with at least one ethoxy or propoxy moiety.
  • the adduct formed by the reaction of the glyceryl fatty acid ester and ethoxylation or propoxylation compound occurs as described in the art.
  • the reaction products are complex and may be formed by other well known conventional processes in the chemical art.
  • the of glycerol portion and fatty acid portion may be ethoxylated or propoxylated separately prior to making the final ester.
  • the ethoxylation or propoxylation adds at least one-quarter, one-half or more ethoxy or propoxy units to the glyceryl fatty acid ester.
  • the ethoxylation adds about 0.5 to 6, more preferably 0.5 to 3 and, still more preferably, 0.5 to 1 ethoxy or propoxy units per final unit of glyceryl fatty acid ester. This generally corresponds to about 0.5 to about 6 moles of ethoxy or propoxy compound per mole of glyceryl fatty acid ester.
  • compositions of the present invention employ a safe and effective amount of ethoxy/propoxy modified glyceryl ester adduct in combination with a suitable pharmaceutically-acceptable topical carrier.
  • Such compositions preferably employ about 0.025 to about 20%, more preferably, about 0.1 to about 10% and, still more preferably, about 1 to about 5%, of the ester by weight of the carrier or final composition.
  • a combination of a glyceryl fatty acid ester compound in a mixture with at least one and preferably two or more acids selected from the group consisting of C6-C18 fatty acids also demonstrates remarkable efficacy.
  • other polyols such as polyglyceryl, sucrose, glucose, sorbitol, and the like sugar esters have been found to work satisfactorily when substituted for the glyceryl fatty acid ester.
  • the useful glyceryl fatty acid eaters include those selected from the groups consisting of glyceryl fatty acid esters having six to twenty-one carbon atoms and fatty acids having six to eighteen carbon atoms.
  • the preferred glyceryl fatty acid ester compounds include monocaprylin, monocaprin, monolaurin, monomyristin, monopalmitolein, ⁇ -monopalmitin, monostearin, monoolein, 1-monolinolein, 1-monolinolenin, and mixtures thereof. Still more preferred compounds include monocaprylin, monocaprin, monolaurin, monomyristin, monopalmitolein, monoolein, monoicosenoin, and monoerucin and mixtures thereof.
  • the highly preferred compounds include monocaprylin, monocaprin, and monolaurin and mixtures thereof. These materials may also be modified by the addition of one or more ethoxy/propoxy units as described herein prior to being employed in the combination.
  • the tertiary mixtures useful herein comprise a glyceryl fatty acid ester, (which may optionally be ethoxylated/propoxylated as described herein); a first fatty acid compound; and a second fatty acid compound.
  • the preferred first and second fatty acid compounds for use in such tertiary mixtures or combinations are straight chain materials and include, without limitation, caproic, heptanoic, caprylic, pelargonic, capric, undecanoic, lauric, myristic, palmitic, heptadecanoic and stearic.
  • the most preferred materials include carproic, heptanoic, carprylic, capric, undecanoic, and lauric.
  • Highly preferred materials include heptanoic, caprylic and capric.
  • the glyceryl fatty acid esters, first fatty acid, and second fatty acid are added to a pharmaceutically-acceptable topical carrier in safe and effective amounts.
  • they are present at a wt:wt ratio of ester: total fatty acid compounds of about 1:10 to about 10:1; more preferably about 1:10 to about 1:1, and still more preferably about 1:10 to about 1:15 with the glyceryl ester being present at a level of about 0.5 to about 5.0%; more preferably about 0.1 to about 2.0%; and still more preferably about 0.5 to about 1.0% of the final composition.
  • the glyceryl fatty acid esters may be ethoxylated or propoxylated under controlled conditions according to conventional methods, such as described above for use in the combination or mixture.
  • compositions of the present invention can be prepared and applied in any suitable form, but are preferably prepared in forms including, without limitation aqueous solutions, lotions, balms, gels, salves, ointments, boluses, suppositories, and the like. Accordingly, the composition and methods may additionally employ conventional compatible pharmaceutically-acceptable carrier materials useful for such applications. It is desirable that the carrier selected be capable of codissolving or suspending the materials used in the composition. Carrier materials suitable for use in the instant composition, therefore, include those well-known for use in the cosmetic and medical arts as a basis for ointments, lotions, creams, salves, aerosols, suppositories, gels and the like.
  • a preferred carrier generally comprised of alcohols, chelating agents, surfactants, parabens and water.
  • the alcohols useful in the compositions and methods of the present invention may be selected from the group consisting of propylene glycol, phenoxyethanol, methanol, ethanol, isopropyl alcohol, and mixtures thereof. In a preferred embodiment they are selected from the group propylene glycol, phenoxyethanol, and mixtures thereof; still more preferred is a mixture of propylene glycol and phenoxyethanol.
  • Surfactants useful in the compositions and methods of the present invention include those selected from the group consisting of sarcosinates, pluronic F68, sodium lauryl sulfate, sorbitan monolaurate, lauryldimethylamineoxide, lauric-diethanolamide, PEG-Esters (polyethylene glycol-dilaurate), coconut hydroxyethyl imidazoline, sodium sulfosuccinate ester of lauric MEA, sodium sulfosuccinate ester of ethoxylated lauryl alcohol, lauric-monoethanolamide, bis-(2-hydroxyethyl) cocoamine oxide ⁇ IPA, bis-(2-hydroxyethyl) tallowamine oxide ⁇ IPA, dimethylcocoamine oxide ⁇ IPA, dimethylcocoamine oxide, (negative inhibitors), polyoxypropylene bases, coconut fatty acid, 2-sulfo-ester, sodium salt, N-coconut oil acyl-N-methyl taurine
  • they are sarcosinates, amine oxides, pluronic F68, sodium lauryl sulfate, and mixtures thereof, more preferred are pluronic F68, sodium lauryl sulfate, amine oxides, and mixtures thereof.
  • Chelating agents useful in the compositions and methods of the present invention include those selected from the group consisting of EDTA, EDTA (Na)2, EDTA (Na)4, TEA, lactic acid, citric acid and mixtures thereof. In a preferred embodiment, they are lactic acid, citric acid, EDTA(Na)2, EDTA (Na)4, TEA, and mixtures thereof, more preferred are lactic acid, EDTA(Na)2, EDTA(Na)4, citric acid and mixtures thereof, highly preferred are lactic acid, EDTA(Na)2, EDTA(Na)4, and mixtures thereof.
  • Parabens useful in the compositions and methods of the present invention may be selected from the group consisting of methyl and propyl parabens. These may possess the methyl alone or in combination with 1-propyl paraben; 4 methyl 1 propyl; and mixtures thereof (and ester).
  • Water q.s. may form the remainder of the carrier and is selected from the group consisting of sterile water, distilled water, deionized water, tap and well water. In a preferred embodiment, they are sterile water, distilled water or deionized water. Emusions may also be employed.
  • the alcohols discussed above may be employed in the compositions and methods of the present invention at any suitable level. In a preferred embodiment, they are present at a level of about 5 to about 60%, more preferred at about 10 to about 30% and, in a highly preferred embodiment, at about 20 to about 25%, by weight per volume of solution.
  • surfactants discussed above may be employed in the compositions and methods of the present invention at any suitable level. In a preferred embodiment, they are present at a level of about 0.25 to about 10%, more preferred at about 2 to about 10% and, highly preferred, at about 4 to about 8%, weight per volume of solution.
  • parabens discussed above may be employed in the compositions and methods of the present invention at any suitable level. In a preferred embodiment, they are present at a level of about 0.5 to 0.5%, more preferred, at about 0.1 to about 0.5% and, highly preferred, at about 0.1 to about 0.3%, weight per volume of solution.
  • the chelators discussed above may be employed in the compositions of the present invention at any suitable level. In a preferred embodiment, they are present at a level of about 0.05 to about 3%, more preferred at about 0.1 to about 0.5% and, highly preferred, at about 0.1 to about 0.2%, weight per volume of solution.
  • compositions of the present invention may additionally employ adjunct components conventionally found in pharmaceutical compositions in their art-established fashion and at their art-established levels.
  • the compositions may contain additional compatible pharmaceutically active materials for combination therapy (such as supplementary antimicrobial, antipruritics, astringents, local anaesthetics, or anti-inflammatory agents), or may contain materials useful in physically formulating various dosage forms of the present invention, such as excipients, dyes perfumes, thickening agents, stabilizers, skin penetration enhancers, preservatives, or antioxidants.
  • Topical treatment regimens comprise applying a safe and effective amount of the compositions described herein directly to the infected or at-risk skin or mucous membrane; particularly, in a veterinary use,on the teats, eyes, ear areas or at any other situs particularly susceptible to microbial contamination.
  • the solution may be sprayed, dipped, wiped, dropped, poured, towelled, or the like, onto the area to be treated.
  • Application can be made once, or preferably several times daily, to prevent bacteria, fungi, mold or the like from forming on the animal's skin, teats, ears and eyes.
  • the following concentrate formula has been found to be active against a selective group of organisms, especially bovine mastitis. Also, the concentrate formula has been found to be non-irritating when applied as a teat dip.
  • Ethoxylated Glycerol Monolaurin 0.5 - 2.0% Caprylic and Capric Acid Mixture 0.5 - 8.0% Phenoxyethanol 0.0 - 2.5% Propylene Glycol 10 - 30% Parabens 0-.0 - 1.0%
  • Monolaurin is ethoxylated by about 0.5 to about 1.5 mole of ethylene oxide by conventional methods.
  • the above formulas may be used in human or veterinary protocols, e.g., in the treatment of nasal tissue disease, ophthalmic disease, fungal corneal infection of horses, pulmonary disease, genital infections, and otitis externa.
  • the formulas may be used in insectidical or germicidal formulation on human or animal skin and plants, catheters, in egg washing, diapers, and wood preservatives.
  • the formulas are also effective in combating fowl mites, ear mites, and ticks.
  • the above formulas are effective against yeasts, gram negative and gram positive organisms and protozoan, more particularly: C. albicans , C. parapsilosis , S. cerevisiae , E. coli , Ps. aeruginosu , S. epidermis , S. aureus , Bacillus subtilis , Streptococcus faecalis , Streptacoccus pyogenec , Corynebacterium , Strep mutans , and Trichomonus vaginalis .
  • the above formula of Example III was diluted 1:8 with water and prophylactically applied to a cow's teats twice a day. As a result, upon analyzing the cow's teats, no substantial growth of micro-organisms was found on the teats. The same treatment was conducted on a cow's teats when the ambient air temperature was substantially below 40°F, and substantially similar results were found. It will be appreciated that substantial growth would normally be found.
  • Formula 4-1 % Weight Monolaurin 1.0 ( Monolaurin EO) Ethoxylated Glycerol Monolaurin 1.75 Caprylic and Capric Mixture 5.0 Pluronic F-68 13.0 EDTA (NA)2 4.0 H2O 75.25
  • Formula 4-2 % Weight (Monolaurin EO) Ethoxylated Glycerol Monolaurin 1.75 Caprylic and Capric Mixture 6.0
  • Example 4-1 and 4-2 were diluted 1:8 in water the dilute was introduced to Strep Agalactial and Staph Aureus organisms. The results illustrate the log reduction of organisms after two minutes of exposure with the dilute.

Abstract

A topical antimicrobial pharmaceutical composition comprising a tertiary mixture comprising:
  • (a) a glyceryl fatty acid ester;
  • (b) a mixture of fatty acids comprising:
    • (i) a first fatty acid antimicrobial agent which is a C₆-C₁₈ fatty acid; and
    • (ii) a second fatty acid antimicrobial agent which is a C₆-C₁₈ fatty acid; and
  • (c) a pharmaceutically acceptable carrier.

Description

  • The present invention relates generally to topical pharmaceutical compositions and, more particularly, to primarily aqueous solutions exhibiting unique antimicrobial properties.
  • The use of antimicrobial agents plays an important part in current medical therapy. This is particularly true in dermatology, where the most effective course of treatment for skin, mucous membranes, hair lesions, or infections frequently includes the use of a topical antimicrobial agent. The present invention includes topical compositions and methods which provide unique performance against a broad spectrum of microbes with excellent speed.
  • Various carboxylic acids are known to be good antimicrobial agents. However, when these acidic solutions are directly applied to an animal's skin, they may interfere with wound healing, cause irritation, inflammation or the like. Also, these solutions have poor solubility properties in water which, in turn, limits the efficacy of aqueous solutions employing these materials.
  • It is also well recognized that there is presently a need for a mild antimicrobial which can be safely applied to skin and mucous membranes, such as an animal's teats, ears and eyes, that will be substantially harmless to the applied area but which will eliminate, arrest, or substantially reduce the growth of bacteria, fungi, mold and the like. The instant invention meets this need.
  • The art discloses that several different carboxylic acid are generally useful in the suppression of fungi, bacteria, molds and the like growth. United States Patent No. 4,406,884 issued to Fawzi discloses a topical antimicrobial composition in the form of an aqueous gel or lotion. This composition contains C₅-C₁₂ fatty acids and has a pH no greater than about 5. United States Patent No. 4,343,798 issued to Fawzi, teaches a topical antimicrobial anti-inflammatory composition having a pH less than about 5 and containing C₅-C₁₂ fatty acids together with a corticosteroid component. United States Patent No. 4,489,097 issued to Stone, teaches the addition of anti-fungal/antibacterial materials to sterile compositions. The antifungal/antibacterial material disclosed is a C₄-C₉ carboxylate antimicrobial agent having a pH of about 6.0 or below. United States Patent No. 4,410,442 issued to Lucas, et al. teaches solutions for use with hydrophilic soft contact lenses containing C₅-C₁₂ fatty acids, especially octanoic acid. United States Patent No. 4,392,848 issued to Lucas, et al. teaches a catheter having a liquid reservoir of an antimicrobial agent flowing through the lumen of the catheter. The antimicrobial agent disclosed is a straight-chain carboxylic acid or carboxylic acid salt having a C₄-C₉ chain. United States Patent No. 4,430,381 issued to Harvey, et al. teaches a process for imparting antimicrobial properties to a material. The antimicrobial being a C₃-C₁₂ alkane, alkene or alkyne monocarboxylate. United States Patent Nos. 4,343,788 and 4,479,795, both issued to Mustacich, et al. teach medical polymers that provide diffusion for certain carboxylate antimicrobial agents. United States Patent No. 4,002,775 issued to Kabara teaches a food grade microbicidal composition having a monoester with a C₁₂ aliphatic fatty acid as its primary microbicide. United States Patent No. 1,772,975 issued to Weiland teaches the use of lactic acid, acetic acid, or combinations thereof, as antiseptics at properly adjusted pH levels. United States Patent No. 2,154,449 issued to Hoffman et al. teaches the use of aliphatic C₃-C₁₂ carboxylic acids and their salts as mold inhibitors in food compositions. United States Patent No. 2,190,714 issued to Hoffman, et al. teaches the addition of a C₃-C₁₂ carboxylic acid to inhibit growth food products other than margarine and sourdough bread. United States Patent No. 3,404,987 to Kooistra, et al. teaches an antimicrobial containing edible mineral salt and edible acid preservative substances, particularly propionic acid. United States Patent No. 2,466,663 issued to Russ, et al. teaches the use of a topical or intravenous caprylic acid solution to combat mycotic infections or growths. United States Patent No. 2,729,586 issued to Peck teaches a therapeutic compositions having at least one salt of a C₃-C₁₁ monocarboxylic acid and water soluble chlorophyll.
  • Other materials also disclose the use of fatty acids for the suppression of fungi, bacteria, mold and the like. Kabara, J., Medium-chain Fatty Acids and Esters as Antimicrobial Agents, Cosmetic and Drug Preservation, Pgs. 275-304, 1984, teaches the use of C₆-C₂₂ saturated and unsaturated fatty acids as antimicrobials. Kabara, J., Toxicological, Bactericidal and Fungicidal Properties of Fatty Acids and Some Derivatives, The Journal of the American Oil Chemists' Society, Vol. 56, No. 11, Pages 760A-767A (1979) teaches the applying of fatty acids to animal skin and eyes. Some fatty acids were found to be skin and eye irritants. Kabara, J., Inhibition of Staphylococlus Aureus In a Model Agar-Meat System By Monolaurin: A Research Note, Journal of Food Safety, Vol. 6, Pgs. 197-201 (1984), teaches the use of monolaurin as a food preservative to combat microorganisms. Kabara, J., Antimicrobial Agents Derives from Fatty Acids, JAOCS, Vol. 61, No. 2, Pgs. 397-403 (1984) teaches the use of saturated and unsaturated fatty acids as antimicrobial agents. Kabara, J., GRAS Antimicrobia Agents for Cosmetic Products, Journal of the Society of Cosmetic Chemists, Vol. 31, Pgs. 1-10 (1980), teaches the composition of monolaurin, a phenol, di-tert-butyl anisole, and a chelating agent such as ethylenediaminetetracetic acid to be useful in destroying gram positive and gram negative bacteria. Schemmel, R., Lynch, P., Krohn, K., and Kabara, J., Monolaurin as an Anticaries Agent, teaches the use of glycerol-monolaurin in inhibiting development of smooth surface caries in rats innoculated with Streptococcus mutants. Kabara, Jr., Ohkawa, M., Ikekawa, T., Katori, T., and Mishikawa, Y., Examination on Antitumor, Immunological and Plant-Growth Inhibitory Effects of Monoglycerides of Caprylic, Capric, and Lauric Acids and Related Compounds, Pharmacological Effects of Lipids, Volume II, Pgs. 263-272 (1985) teaches the use of the monoglycerides or caprylic, capric and lauric acids for regulating antitumor, immunological, and plant-growth activity. Li, C., and Kabara, J., Effects of Lauricidin on Fomes Annosus and Phellinus Weirii, AOCS Monograph No. 5, Pgs. 45-47 (1978) teaches the use of monolaurin in combating root rot fungi in coniferous forest. Kenney, D., Cosmetic Formulas Preserved With Food-Grade Chemicals, Cosmetics and Toiletries, Part 1, Vol. 97, Pgs. 71-76 (1982) and Kabara, J. and Wernette, C., Cosmetic Formulas Preserved with Food-Grade Chemicals, Cosmetics and Toiletries, Part II, Vol. 97, Pgs. 77-84 (1982) teaches the use of monoglyceride emulsifier, food-grade phenols and a chelator in the preservation of cosmetics. Kabara, J., A New Preservative System For Food, Journal of Food Safety, Volume 4, Pgs. 13-25 (1982) teaches the use of monolaurin, a food grade phenolic, and a chelator as an antimicrobial for the preservation of food. Branan, A. and Davison, P. Antimicrobials in Foods, Marcel Dekker, New York 1983, Pgs. 109-140 teaches the use of saturated, unsaturated and esters of fatty acids as antimicrobials and the use of these compounds for food preservation. Kabara, J., Fatty Acids and Derivatives as Antimicrobial Agents - A Review, AOCS Monograph No. 5, Pgs. 1-14 (1978) teaches the use of saturated, unsaturated and esters of fatty acids as antimicrobials and the use of these compounds for permeating microorganism cellular membranes for killing the microorganism.
  • The art also teaches many methods of ethoxylation. Nonionic Surfactants, Schick, M.J., Marcel Dekker, Inc., New York (1966) and Dillan, K., Effects of the Ethylene Oxide Distribution on Nonionic Surfactant Properties, JAOCS, Vol. 62, No. 7, Pgs. 1144-1151 (1985) teach the ethoxylation of primary alcohols to product nonionic surfactants.
  • The above discussion clearly reflects the ambiguous state of the art with regard to the suitability and selection of fatty acid-based materials as antimicrobials, especially in the topical or preservative mode. The art disclosed materials vary widely in their efficacy and possess an even wider variety of side effects, particularly when employed in veterinary topical materials under adverse or stressful conditions. (The term glyceryl and glycerol are used interchangeably herein when describing fatty acid esters.)
  • The present invention relates to preservative pharmaceutical compositions and methods, especially those useful when applied topically and/or those which exhibit good shelf stability. The present invention relates to the discovery that the overall antimicrobial efficacy and pharmaceutical acceptability of certain glycerol fatty acid esters can be dramatically increased by either (1) the addition of certain ether groups, particularly ethoxy and propoxy units; (2) by use in combination with select fatty acid materials, (3) a combination of (1) and (2). Such modified glycerol fatty acid ester materials retain or exhibit an improved overall spectrum and speed of activity while producing fewer or reduced (in severity) side effects. Such a material is especially useful when compared to the unmodified material in that it produces much less irritation at the site of application.
  • The present invention further relates to the discovery that the spectrum and speed of activity of both modified and unmodified fatty acid esters can be significantly improved when used in a tertiary mixture or in combination with a mixture of two or more C₆-C₁₈ fatty acids, preferably C₆-C₁₂ fatty acids. All these materials are in turn employed in combination with a topical carrier. Such materials provide effective topical antimicrobial activity and are accordingly useful in the treatment and prevention of conditions which are caused, or aggravated by microbial organisms (including viruses) on skin and mucous membranes or are otherwise relates to microbes.
  • Also, the compositions of the present invention exhibit exceptional preservative applications. In addition to preserving the final composition and stabilizing the material to increase the efficacy in cold climate or conditions, the present compositions provide outstanding preservative characteristics when added primarily as a preservative in food stuffs, cosmetic formulations and pharmaceutical compositions (topical; parenteral; intramuscular; and intravenous). The preservative applications are further discussed in my copending patent application entitled "ANTIMICROBIAL PRESERVATIVE COMPOSITIONS", filed on the same day as the present application.
  • For example, such compositions are useful in veterinary applications as a teat dip, an eye medication and an ear medication. A safe and effective amount of the compositions, described above, to an animal in need of such treatment on the area to be treated one or more times daily.
  • It is well known that in general the ethoxylation or propoxylation of an antimicrobial agent generally renders that agent biologically inactive; at a minimum, the activity is substantially reduced. See Nonionic Surfactants, Martin J. Schick, Marcel Dekker, Inc., New York, New York Chap. 28, Pgs. 958-960.
  • Unexpectedly, it has been found that the addition of a select number of ethoxy or propoxy units to a glyceryl fatty acid ester results in an antimicrobial agent with good activity and reduced side effects. Further, it has been discovered that the formed narrow ranged ethoxylates possess better surface-active properties when compared with the broad distribution range adducts. Also, the narrow range ethoxylates seem to act faster and have a better detergent activity that the broad distribution adducts; further, this fastener germicidal and detergent activity does not correlate with what is expected of non-ionic ethoxylates. Generally, non-ionic ethoxylates such as TWEEW 80 and SPAN 20 are germicidally inactive. While not intending to be bound by theory, it appears that controlled ethoxylation or propoxylation adds to available hydroxyl radicals by ring cleavage with regeneration of the hydroxyl group. This reaction is an addition reaction without termination. Such ethoxylation is discussed in more detail in Dillan, K., Effects of the Ethylene Oxide Distribution of Nonionic Surfactant Properties, JAOCS, Vol. 62, Pgs. 1144-1151, 1985 which is herein incorporated by reference.
  • The glyceryl fatty acid ester which is to be ethoxylated or propoxylated for use in the compositions and methods of the present invention is preferably selected from the group consisting of polyhydric alcohols, polyglycerols, sucrose, glucose, sorbitol, propylenediol and glyceryl fatty acid esters having about six to about twenty-one carbon atoms. Such preferred compounds include monocaprylin, monocaprin, monolaurin, monomyristin, monopalmitolein, α-monopalmitin, monostearin, monoolein, 1-monolinolein, 1-monolinolenin, and mixtures thereof. Still more preferred are monocaprylin, monocaprin, monolaurin, monomyristin, monopalmitolein, monoolein, monoicosenin and monoerucin and mixtures thereof. The highly preferred compounds include monocaprylin, monocaprin and monolaurin and mixtures thereof. Monolaurin is most highly preferred taking into account cost, availability and activity.
  • The glyceryl fatty acid esters are ethoxylated or propoxylated by conventional ethoxylating or propoxylating compounds and techniques. The compounds are preferably selected from the group consisting of ethylene oxide, propylene oxide, and mixtures thereof, and similar ringed compounds which provide a material which is effective. Most preferably, the ethoxylation compound is selected from the group consisting of ethylene oxide, propylene oxide and mixtures thereof.
  • The glyceryl fatty acid esters are ethoxylated or propoxylated under controlled conditions preferably within a narrow range according to conventional methods, such as those in the Dillan article further incorporated by reference. The glyceryl fatty acid esters are ethoxylated or propoxylated by a suitable amount of ethoxylate or propoxylate compound. In a preferred embodiment, the ethoxylation or propoxylation compound is reacted at a level of about 0.25 to about 25, more preferably about 0.5 to about 20 moles, more preferably, at about 0.5 to about 3.0 moles and, still more preferably, at about 0.5 to about 1.0 moles of ethoxylate or propoxylate per mole of glyceryl ester. Thus, the resulting products useful in the compositions and methods of the present invention generally contain at least about 1 mole of ethoxylate or propoxylate per four moles of glyceryl ester; in other words there is at least about one-quarter, and preferably at least about one-half, ether unit or moiety per glyceryl fatty acid ester unit or molecule. This could be further expressed as stating that useful ethoxylated glyceryl fatty acid esters of the present invention are esters wherein at least one-quarter, and preferably at least one-half of the total glyceryl ester has reunited with at least one ethoxy or propoxy moiety.
  • Generally, the adduct formed by the reaction of the glyceryl fatty acid ester and ethoxylation or propoxylation compound occurs as described in the art. However, it is noted that the reaction products are complex and may be formed by other well known conventional processes in the chemical art. For example, the of glycerol portion and fatty acid portion may be ethoxylated or propoxylated separately prior to making the final ester.
  • The ethoxylation or propoxylation adds at least one-quarter, one-half or more ethoxy or propoxy units to the glyceryl fatty acid ester. Preferably the ethoxylation adds about 0.5 to 6, more preferably 0.5 to 3 and, still more preferably, 0.5 to 1 ethoxy or propoxy units per final unit of glyceryl fatty acid ester. This generally corresponds to about 0.5 to about 6 moles of ethoxy or propoxy compound per mole of glyceryl fatty acid ester.
  • The pharmaceutical compositions of the present invention employ a safe and effective amount of ethoxy/propoxy modified glyceryl ester adduct in combination with a suitable pharmaceutically-acceptable topical carrier. Such compositions preferably employ about 0.025 to about 20%, more preferably, about 0.1 to about 10% and, still more preferably, about 1 to about 5%, of the ester by weight of the carrier or final composition.
  • As discussed above, it has been further observed that a combination of a glyceryl fatty acid ester compound (either ethoxylated/propoxylated and non-ethoxylated/propoxylated) in a mixture with at least one and preferably two or more acids selected from the group consisting of C₆-C₁₈ fatty acids also demonstrates remarkable efficacy. Also, other polyols such as polyglyceryl, sucrose, glucose, sorbitol, and the like sugar esters have been found to work satisfactorily when substituted for the glyceryl fatty acid ester. The useful glyceryl fatty acid eaters include those selected from the groups consisting of glyceryl fatty acid esters having six to twenty-one carbon atoms and fatty acids having six to eighteen carbon atoms. The preferred glyceryl fatty acid ester compounds include monocaprylin, monocaprin, monolaurin, monomyristin, monopalmitolein, α-monopalmitin, monostearin, monoolein, 1-monolinolein, 1-monolinolenin, and mixtures thereof. Still more preferred compounds include monocaprylin, monocaprin, monolaurin, monomyristin, monopalmitolein, monoolein, monoicosenoin, and monoerucin and mixtures thereof. The highly preferred compounds include monocaprylin, monocaprin, and monolaurin and mixtures thereof. These materials may also be modified by the addition of one or more ethoxy/propoxy units as described herein prior to being employed in the combination. The tertiary mixtures useful herein comprise a glyceryl fatty acid ester, (which may optionally be ethoxylated/propoxylated as described herein); a first fatty acid compound; and a second fatty acid compound. The preferred first and second fatty acid compounds for use in such tertiary mixtures or combinations are straight chain materials and include, without limitation, caproic, heptanoic, caprylic, pelargonic, capric, undecanoic, lauric, myristic, palmitic, heptadecanoic and stearic. The most preferred materials include carproic, heptanoic, carprylic, capric, undecanoic, and lauric. Highly preferred materials include heptanoic, caprylic and capric.
  • The glyceryl fatty acid esters, first fatty acid, and second fatty acid are added to a pharmaceutically-acceptable topical carrier in safe and effective amounts. In a preferred embodiment, they are present at a wt:wt ratio of ester: total fatty acid compounds of about 1:10 to about 10:1; more preferably about 1:10 to about 1:1, and still more preferably about 1:10 to about 1:15 with the glyceryl ester being present at a level of about 0.5 to about 5.0%; more preferably about 0.1 to about 2.0%; and still more preferably about 0.5 to about 1.0% of the final composition.
  • The glyceryl fatty acid esters may be ethoxylated or propoxylated under controlled conditions according to conventional methods, such as described above for use in the combination or mixture.
  • The compositions of the present invention can be prepared and applied in any suitable form, but are preferably prepared in forms including, without limitation aqueous solutions, lotions, balms, gels, salves, ointments, boluses, suppositories, and the like. Accordingly, the composition and methods may additionally employ conventional compatible pharmaceutically-acceptable carrier materials useful for such applications. It is desirable that the carrier selected be capable of codissolving or suspending the materials used in the composition. Carrier materials suitable for use in the instant composition, therefore, include those well-known for use in the cosmetic and medical arts as a basis for ointments, lotions, creams, salves, aerosols, suppositories, gels and the like. A preferred carrier generally comprised of alcohols, chelating agents, surfactants, parabens and water.
  • The alcohols useful in the compositions and methods of the present invention may be selected from the group consisting of propylene glycol, phenoxyethanol, methanol, ethanol, isopropyl alcohol, and mixtures thereof. In a preferred embodiment they are selected from the group propylene glycol, phenoxyethanol, and mixtures thereof; still more preferred is a mixture of propylene glycol and phenoxyethanol.
  • Surfactants useful in the compositions and methods of the present invention include those selected from the group consisting of sarcosinates, pluronic F68, sodium lauryl sulfate, sorbitan monolaurate, lauryldimethylamineoxide, lauric-diethanolamide, PEG-Esters (polyethylene glycol-dilaurate), coconut hydroxyethyl imidazoline, sodium sulfosuccinate ester of lauric MEA, sodium sulfosuccinate ester of ethoxylated lauryl alcohol, lauric-monoethanolamide, bis-(2-hydroxyethyl) cocoamine oxide·IPA, bis-(2-hydroxyethyl) tallowamine oxide·IPA, dimethylcocoamine oxide·IPA, dimethylcocoamine oxide, (negative inhibitors), polyoxypropylene bases, coconut fatty acid, 2-sulfo-ester, sodium salt, N-coconut oil acyl-N-methyl taurine, sodium salt, lauroyl sarcosine, 30% sodium lauryl sarcosinate, sodium lauroyl sarcosinate, myristoyl sarcosine, oleoyl sarcosine, stearoyl sarcosine, polyoxyethelene 21 stearyl ether (0.1% BHA & 0.005% citric acid as preservatives), lauroamphoglycinate, lauroamphocarboxyglycinate, lauroamphocarboxypropinate, lauroamphocarboxyglycinate-sulfanate, sodium lauryl sulfate (66% lauryl, 27% myristyl, 71% cetyl), polyoxyethylene sorbitan mono-oleate, and mixtures thereof. In a preferred embodiment they are sarcosinates, amine oxides, pluronic F68, sodium lauryl sulfate, and mixtures thereof, more preferred are pluronic F68, sodium lauryl sulfate, amine oxides, and mixtures thereof.
  • Chelating agents useful in the compositions and methods of the present invention include those selected from the group consisting of EDTA, EDTA (Na)₂, EDTA (Na)₄, TEA, lactic acid, citric acid and mixtures thereof. In a preferred embodiment, they are lactic acid, citric acid, EDTA(Na)₂, EDTA (Na)₄, TEA, and mixtures thereof, more preferred are lactic acid, EDTA(Na)₂, EDTA(Na)₄, citric acid and mixtures thereof, highly preferred are lactic acid, EDTA(Na)₂, EDTA(Na)₄, and mixtures thereof.
  • Parabens useful in the compositions and methods of the present invention may be selected from the group consisting of methyl and propyl parabens. These may possess the methyl alone or in combination with 1-propyl paraben; 4 methyl 1 propyl; and mixtures thereof (and ester).
  • Water q.s. may form the remainder of the carrier and is selected from the group consisting of sterile water, distilled water, deionized water, tap and well water. In a preferred embodiment, they are sterile water, distilled water or deionized water. Emusions may also be employed.
  • The alcohols discussed above may be employed in the compositions and methods of the present invention at any suitable level. In a preferred embodiment, they are present at a level of about 5 to about 60%, more preferred at about 10 to about 30% and, in a highly preferred embodiment, at about 20 to about 25%, by weight per volume of solution.
  • The surfactants discussed above may be employed in the compositions and methods of the present invention at any suitable level. In a preferred embodiment, they are present at a level of about 0.25 to about 10%, more preferred at about 2 to about 10% and, highly preferred, at about 4 to about 8%, weight per volume of solution.
  • The parabens discussed above may be employed in the compositions and methods of the present invention at any suitable level. In a preferred embodiment, they are present at a level of about 0.5 to 0.5%, more preferred, at about 0.1 to about 0.5% and, highly preferred, at about 0.1 to about 0.3%, weight per volume of solution.
  • The chelators discussed above may be employed in the compositions of the present invention at any suitable level. In a preferred embodiment, they are present at a level of about 0.05 to about 3%, more preferred at about 0.1 to about 0.5% and, highly preferred, at about 0.1 to about 0.2%, weight per volume of solution.
  • The compositions of the present invention may additionally employ adjunct components conventionally found in pharmaceutical compositions in their art-established fashion and at their art-established levels. Thus, for example, the compositions may contain additional compatible pharmaceutically active materials for combination therapy (such as supplementary antimicrobial, antipruritics, astringents, local anaesthetics, or anti-inflammatory agents), or may contain materials useful in physically formulating various dosage forms of the present invention, such as excipients, dyes perfumes, thickening agents, stabilizers, skin penetration enhancers, preservatives, or antioxidants.
  • Topical treatment regimens according to the practice of this invention comprise applying a safe and effective amount of the compositions described herein directly to the infected or at-risk skin or mucous membrane; particularly, in a veterinary use,on the teats, eyes, ear areas or at any other situs particularly susceptible to microbial contamination. The solution may be sprayed, dipped, wiped, dropped, poured, towelled, or the like, onto the area to be treated. Application can be made once, or preferably several times daily, to prevent bacteria, fungi, mold or the like from forming on the animal's skin, teats, ears and eyes.
  • The following examples illustrate the invention.
  • EXAMPLE 1
  • The following formulae have been found to be active against a substantial group of organisms. Also, these formulae have been found to be substantially non-irritating as an ear/eye preparation.
    Ethoxylated Glycerol Monolaurin (Monolaurin EO) 0.05 - 1.0%
    Caprylic Acid/Capric Acid Mixture 0.1 - 5.0%
    Parabens 0.0 - 0.3%
    Pluronic F68 1.0 - 10%
    Phenoxylethanol 0.0 - 1.0%
    EDTA (Na)₂ 0.05 - 0.3%
    Water 82.4 - 98.65%

    Glycerol monolaurin is ethoxylated by about one mole ethylene oxide per mole of glycerol monolaurin by conventional ethoxylation methods as described herein.
  • EXAMPLE 2
  • The following concentrate formula has been found to be active against a selective group of organisms, especially bovine mastitis. Also, the concentrate formula has been found to be non-irritating when applied as a teat dip.
    Ethoxylated Glycerol Monolaurin 0.5 - 2.0%
    Caprylic and Capric Acid Mixture 0.5 - 8.0%
    Phenoxyethanol 0.0 - 2.5%
    Propylene Glycol 10 - 30%
    Parabens 0-.0 - 1.0%
    Pluronic F68 5 - 13.0%
    EDTA (Na)₂/Lactic Acid 1 - 15%
    H₂O 30 - 80% Monolaurin

    is ethoxylated by about 0.5 to about 1.5 mole of ethylene oxide by conventional methods.
  • Also, the above formulas (Examples I and II) may be used in human or veterinary protocols, e.g., in the treatment of nasal tissue disease, ophthalmic disease, fungal corneal infection of horses, pulmonary disease, genital infections, and otitis externa. The formulas may be used in insectidical or germicidal formulation on human or animal skin and plants, catheters, in egg washing, diapers, and wood preservatives. The formulas are also effective in combating fowl mites, ear mites, and ticks.
  • The above formulas are effective against yeasts, gram negative and gram positive organisms and protozoan, more particularly: C. albicans, C. parapsilosis, S. cerevisiae, E. coli, Ps. aeruginosu, S. epidermis, S. aureus, Bacillus subtilis, Streptococcus faecalis, Streptacoccus pyogenec, Corynebacterium, Strep mutans, and Trichomonus vaginalis.
  • EXAMPLE 3
  • The following formula concentrate was tested against a yeast, a gram negative and a gram positive organism:
    % Weight
    (Monolaurin EO) Ethoxylated Glycerol Monolaurin 1.0
    Caprylic and Capric Mixture 1.5
    Propylene Glycol 22
    Parabens 0.5
    Phenoxyethanol 2.5
    Pluronic F-68 5.0
    EDTA (NA)₂ 2.0
    dH₂O q.s.

    After the formula was diluted 1:10 in water, the dilute was introduced to E. coli and to C. parapsilosis organisms. The results are as follows:
    E. COLI
    Time Colony Forming Units/ml
    To 4.3x10⁶
    T=2 mins <30
    T=10 mins <30
    C. PARAPSILOSIS
    Time Colony Forming Units/ml
    To 1.7x10⁶
    T=2 min. 2.5x10³
    T=10 min. <30

    The formula of Example III was diluted 1:20 in water and then the dilute was introduced to S. aureus. The results are as follows:
    S. AUREUS
    Time Colony Forming Units/ml
    To 1.6x10⁶
    T=2 min. <5.0x10¹
    T=10 min. <30

    The above formula of Example III was diluted 1:8 with water and prophylactically applied to a cow's teats twice a day. As a result, upon analyzing the cow's teats, no substantial growth of micro-organisms was found on the teats. The same treatment was conducted on a cow's teats when the ambient air temperature was substantially below 40°F, and substantially similar results were found. It will be appreciated that substantial growth would normally be found.
  • EXAMPLE 4
  • Formula 4-1
    % Weight
    Monolaurin 1.0
    ( Monolaurin EO) Ethoxylated Glycerol Monolaurin 1.75
    Caprylic and Capric Mixture 5.0
    Pluronic F-68 13.0
    EDTA (NA)₂ 4.0
    H₂O 75.25
    Formula 4-2
    % Weight
    (Monolaurin EO) Ethoxylated Glycerol Monolaurin 1.75
    Caprylic and Capric Mixture 6.0
    Pluronic F-68 13.0
    Lactic Acid (85%) 15.0
    H₂O 64.25

    After the formulas of Example 4-1 and 4-2 were diluted 1:8 in water the dilute was introduced to Strep Agalactial and Staph Aureus organisms. The results illustrate the log reduction of organisms after two minutes of exposure with the dilute. Also listed are the log reduction results of other solutions used in the field.
    Log Reduction of Organisms
    Time Strep Agalactial Staph Aureus
    Example 4-1 T=2 min. 3.1 2.7
    Example 4-2 T=2 min. 4.3 5.1
    Tegragon (Quaternary complex) T=2 min. 1.0 2.0
    Teat Care (Chlorhexadine) T=2 min. 1.7 2.0
    All Day (Sorbic Acid) T=2 min. - 1.8
    Quartermate (2000 Lodophor) T=2 min. 2.2 2.4
  • EXAMPLE 5
  • The following formula was tested against the identified organisms with the following results.
    Formula 5
    % Weight
    (Monolaurin EO) Ethoxylated Glycerol Monolaurin 0.15
    Caprylic and Capric Mixture 0.30
    Parabens 0.05
    Dowanol 0.1
    Pluronic F-68 5.0
    EDTA (Na)₂ 0.1
    EDTA (Na)₄ 0.1
    d H₂O 94.2
    Ps AERUGINOSA
    Time Colony Forming Units/ml
    To 1.2x10⁶
    T=2 min. <30
    T=10 min. <30
    E. COLI
    Time Colony Forming Units/ml
    To 3.0x10⁶
    T=2 min. <30
    T=10 min. <30
  • EXAMPLE 6
  • The following formula was tested against the identified organism with the following results.
    % Weight
    (Monolaurin EO) Ethoxylated Glycerol Monolaurin 0.15
    Caprylic and Capric Mixture 0.30
    Dowanol 0.10
    Pluronic F-68 5.0
    EDTA (Na)₂ 0.1
    EDTA (Na)₄ 0.1
    d H₂O 94.25
    Ps AERUGINOSA
    Time Colony Forming Units/ml
    To 1.2x10⁶
    T₂ <30
    T₁₀ <30
    E. COLI
    Time Colony Forming Units/ml
    To 3.0x10⁶
    T=2 min. < 30
    T=10 min. < 30
  • While the above summarizes the present invention, it will become apparent to those skilled in the art that modifications, variations and alterations may be made without deviating from the scope and spirit of the present invention as described and claimed herein.

Claims (12)

  1. A topical antimicrobial pharmaceutical composition comprising a tertiary mixture comprising:
    (a) a glyceryl fatty acid ester;
    (b) a mixture of fatty acids comprising:
    (i) a first fatty acid antimicrobial agent which is a C₆-C₁₈ fatty acid; and
    (ii) a second fatty acid antimicrobial agent which is a C₆-C₁₈ fatty acid; and
    (c) a pharmaceutically acceptable carrier.
  2. A topical antimicrobial pharmaceutical composition according to claim 1 wherein the ratio by weight of the ester to the first and second fatty acids combined is 1:10 to 10:1.
  3. A topical antimicrobial pharmaceutical composition according to claim 1 or 2 wherein the first fatty acid and/or the second fatty acid is a straight chain fatty acid having from six to twelve carbon atoms.
  4. A topical antimicrobial pharmaceutical composition according to any one of claims 1 to 3 wherein the glyceryl fatty acid ester is a monoester.
  5. A topical antimicrobial pharmaceutical composition according to claim 4 wherein the monoester contains 6 to 21 carbon atoms.
  6. A topical antimicrobial pharmaceutical composition according to claim 5 wherein the monoester is monocaprylin, monocaprin, monolaurin, monomyristin, monopalmitolein, monolein, monoicosenoin, monoerucin or a mixture thereof.
  7. A topical antimicrobial pharmaceutical composition according to any one of claims 4 to 6 wherein the monoester is present in an amount of 0.025 to 20.0% by weight of the composition.
  8. A topical antimicrobial pharmaceutical composition according to any one of claims 1 to 7 in which the carrier comprises an alcohol, chelating agent, surfactant, paraben, water, or a mixture thereof.
  9. A topical antimicrobial pharmaceutical composition according to claim 8 wherein the pharmaceutical carrier comprises an alcohol which is propylene glycol, phenoxyethanol, methanol, ethanol, isopropyl alcohol, or a mixture thereof; a chelating agent which is EDTA, Na₂(EDTA), Na₄(EDTA), TEA, lactic acid, critric acid or a mixture thereof; a surfactant which is a sarcosinate, an amine oxide, pluronic 68, sodium lauryl sulfate or a mixture thereof; or a paraben which is methyl paraben, propyl paraben or a mixture thereof.
  10. A topical antimicrobial pharmaceutical composition according to claim 8 or 9 which comprises 5% to 60% by volume of the alcohol; 0.25% to 10% by weight of the surfactant; 0.05% to 5% by weight of the parabens; 0.05% to 4% by weight of the chelating agent.
  11. A composition according to any one of claims 1 to 10 for use as a topical antimicrobial agent.
  12. Use of a composition according to any one of claims 1 to 11 in the preparation of a topical antimicrobial medicament.
EP92119054A 1986-04-21 1987-04-21 Topical antimicrobial pharmaceutical compositions Expired - Lifetime EP0530861B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85415486A 1986-04-21 1986-04-21
US854154 1986-04-21
EP87303487A EP0243145B1 (en) 1986-04-21 1987-04-21 Topical antimicrobial pharmaceutical compositions

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP87303487A Division-Into EP0243145B1 (en) 1986-04-21 1987-04-21 Topical antimicrobial pharmaceutical compositions
EP87303487.0 Division 1987-04-21

Publications (3)

Publication Number Publication Date
EP0530861A2 true EP0530861A2 (en) 1993-03-10
EP0530861A3 EP0530861A3 (en) 1993-04-07
EP0530861B1 EP0530861B1 (en) 1998-09-09

Family

ID=25317877

Family Applications (2)

Application Number Title Priority Date Filing Date
EP87303487A Expired - Lifetime EP0243145B1 (en) 1986-04-21 1987-04-21 Topical antimicrobial pharmaceutical compositions
EP92119054A Expired - Lifetime EP0530861B1 (en) 1986-04-21 1987-04-21 Topical antimicrobial pharmaceutical compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP87303487A Expired - Lifetime EP0243145B1 (en) 1986-04-21 1987-04-21 Topical antimicrobial pharmaceutical compositions

Country Status (8)

Country Link
EP (2) EP0243145B1 (en)
JP (1) JP2543883B2 (en)
AU (1) AU607133B2 (en)
CA (1) CA1302280C (en)
DE (2) DE3752217T2 (en)
ES (2) ES2122980T3 (en)
IE (2) IE940583L (en)
NZ (1) NZ219973A (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007616A1 (en) * 1993-09-14 1995-03-23 Minnesota Mining And Manufacturing Company Disinfectant composition
EP0676190A2 (en) * 1994-04-07 1995-10-11 Beiersdorf Aktiengesellschaft Composition effective against foot odour containing monoglycerolesters of fatty acids
WO1996002228A1 (en) * 1994-07-18 1996-02-01 Minnesota Mining And Manufacturing Company Oral disinfectant for companion animals
EP0704213A1 (en) * 1994-09-29 1996-04-03 Beiersdorf Aktiengesellschaft Dermatologic compositions containing fatty-acid glycerides for the treatment of superinfections
EP0705605A3 (en) * 1994-09-29 1996-05-01 Beiersdorf Ag
EP0709082A2 (en) 1994-10-28 1996-05-01 Beiersdorf Aktiengesellschaft Combinations of active ingredients based on wool wax acids and glycerides of saturated fatty acids efficient against impure skin, slight forms of acne as well as propionibacterium acnes
US5569461A (en) * 1995-02-07 1996-10-29 Minnesota Mining And Manufacturing Company Topical antimicrobial composition and method
DE19631004A1 (en) * 1996-08-01 1998-02-05 Beiersdorf Ag Deodorizing combinations of active substances based on woollysilicic acids, partial glycerides and aryl compounds
EP0904693A1 (en) * 1997-09-26 1999-03-31 Ecolab Inc. Pseudoplastic film-forming acidic chlorite composition as teat dip
EP0906724A1 (en) * 1997-09-26 1999-04-07 Ecolab Inc. Pseudoplastic film-forming acidic chlorite composition as teat dip
WO2000045649A1 (en) * 1999-02-05 2000-08-10 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US6123966A (en) * 1998-09-03 2000-09-26 Alcide Corporation Stabilized two-part disinfecting system and compositions and methods related thereto
US6310013B1 (en) 1999-10-27 2001-10-30 Ecolab Inc. Lubricant compositions having antimicrobial properties and methods for manufacturing and using lubricant compositions having antimicrobial properties
US6740679B1 (en) 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US6756051B1 (en) * 2000-11-15 2004-06-29 Li-Lan H. Chen Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same
US6967189B2 (en) 2002-11-27 2005-11-22 Ecolab Inc. Buffered lubricant for conveyor system
WO2005023233A3 (en) * 2003-09-09 2005-12-22 3M Innovative Properties Co Antimicrobial compositions and methods
US7090882B2 (en) 2003-06-12 2006-08-15 Cargill, Incorporated Antimicrobial salt solutions for food safety applications
WO2006099325A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
WO2007134055A1 (en) * 2006-05-10 2007-11-22 Medtronic Xomed, Inc. Antibacterial extracellular polysaccharide solvating system
US7553871B2 (en) * 1996-02-20 2009-06-30 Gea Westfaliasurge, Inc. Fatty acid antimicrobial
WO2009099419A2 (en) * 2008-01-30 2009-08-13 Taylor Fresh Foods, Inc Antimicrobial compositions and methods of use thereof
US7588696B2 (en) 2003-06-12 2009-09-15 Cargill, Incorporated Antimicrobial water softener salt and solutions
US7592370B2 (en) 1999-02-05 2009-09-22 Baylor Research Institute Fatty acid treatment for cardiac patients
US7658959B2 (en) 2003-06-12 2010-02-09 Cargill, Incorporated Antimicrobial salt solutions for food safety applications
US7883732B2 (en) 2003-06-12 2011-02-08 Cargill, Incorporated Antimicrobial salt solutions for cheese processing applications
US8486472B2 (en) 2006-01-18 2013-07-16 Cargill, Incorporated Antimicrobial salt solutions for food safety applications
US8697748B2 (en) 2004-07-02 2014-04-15 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
US8729049B2 (en) 2009-09-28 2014-05-20 Woresan Gmbh Leaven-based mixture
US9826770B2 (en) 2005-03-10 2017-11-28 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxycarboxylic acids
GB2559173A (en) * 2017-01-30 2018-08-01 Kingston Univ Higher Education Corporation Prophylaxis and treatment of neisseria Gonorrhoeae eye infection
US10918618B2 (en) 2005-03-10 2021-02-16 3M Innovative Properties Company Methods of reducing microbial contamination

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU619256B2 (en) * 1988-03-03 1992-01-23 Connetics Australia Pty Ltd Acne treatment
EP0406275A4 (en) * 1988-03-21 1992-05-06 Daratech Pty. Ltd. Teat dip
EP0462964B1 (en) * 1989-03-13 1998-07-22 Cellegy Pharmaceuticals, Inc. Topical compositions containing aliphatic amines for the treatment of skin diseases
US5308868A (en) * 1989-03-21 1994-05-03 Bruce Kefford Teat dip
US5641503A (en) * 1989-04-27 1997-06-24 Mcneil-Ppc, Inc. Additives to tampons
NZ250714A (en) * 1990-10-30 1996-05-28 Mcneil Ppc Inc Liquid composition comprising esters of higher fatty acids for use as a vaginal douche and to prevent toxic shock toxin production
NZ264247A (en) * 1990-10-30 1996-07-26 Mcneil Ppc Inc Absorbent product containing mono- or diesters of a polyhydric alcohol and a c8-18 fatty acid having at least one free hydroxyl group in sufficient amount to inhibit the production of enterotoxins a, b and c by staph. aureus
US5219887A (en) * 1991-06-07 1993-06-15 Minnesota Mining And Manufacturing Company Disinfecting shampoo composition for animals
US5378731A (en) * 1991-06-07 1995-01-03 Minnesota Mining And Manufacturing Company Medicated shampoo
SE500777C2 (en) * 1992-04-14 1994-08-29 Hydro Pharma Ab Antimicrobial composition with potentiated effect containing, inter alia, certain monoglycerides, process for their preparation and their use
US5520920A (en) * 1992-08-28 1996-05-28 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
AU666957B2 (en) * 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
DE4229737C2 (en) * 1992-09-05 1996-04-25 Beiersdorf Ag Deodorizing cosmetic products containing fatty acids
DE4234188C2 (en) * 1992-10-10 1996-01-11 Beiersdorf Ag Antimycotic cosmetic and dermatological uses
DE4237367C2 (en) * 1992-11-05 1995-10-12 Beiersdorf Ag Use of fatty acid esters in cosmetic or dermatological preparations
US5472703A (en) * 1993-03-02 1995-12-05 Johnson & Johnson Vision Products, Inc. Ophthalmic lens with anti-toxin agent
US5866149A (en) * 1993-12-10 1999-02-02 L'oreal Composition for making up the eyelashes and the eyebrows stabilized oxyethylenated derivatives
FR2713481B1 (en) * 1993-12-10 1996-05-24 Oreal Composition for making up the eyelashes and eyebrows stabilized by a mixture of oxyethylenated glyceryl acylates or a mixture of oxyethylenated and non-oxyethylenated glyceryl acylates.
DE4429467C2 (en) 1994-08-19 1997-10-02 Beiersdorf Ag Deodorizing cosmetic products
EP0702950A1 (en) 1994-09-26 1996-03-27 Beiersdorf Aktiengesellschaft Use of fatty acids against skin superinfections
DE4435288A1 (en) * 1994-10-01 1996-04-04 Beiersdorf Ag Dermatological preparations against superinfections containing ethoxylated and / or propoxylated alcohols and / or carboxylic acids
DE4435290A1 (en) * 1994-10-01 1996-04-04 Beiersdorf Ag Dermatological preparations containing fatty acids and fatty acid glycerides against superinfections
DE4436538A1 (en) * 1994-10-13 1996-04-18 Beiersdorf Ag Drug combinations for use against superinfections containing wool wax acid mixtures and other fatty acids
DE4436537A1 (en) * 1994-10-13 1996-04-18 Beiersdorf Ag Dermatological preparations containing fatty acids and fatty acid glycerides against superinfections
FR2750607B1 (en) * 1996-07-08 1998-10-30 Cfpi Ind FOOD QUALITY BACTERICIDE COMPOSITION AND METHOD FOR IMPLEMENTING SAME
US6444710B1 (en) 1998-10-27 2002-09-03 Alcon Manufacturing, Ltd. Use of certain fatty acid/amino acid soaps to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
DE69913559T2 (en) * 1998-10-27 2004-11-11 Alcon Manufacturing Ltd., Fort Worth PRESERVATION SYSTEM FOR TOPICALLY AVAILABLE PHARMACEUTICAL COMPOSITIONS
DE69904498T2 (en) 1998-10-27 2003-04-24 Alcon Lab Inc PRESERVATIVES FOR LOCAL PHARMACEUTICAL PREPARATIONS CONTAINING A SOAP CONTAINING FATTY ACID / AMINO ACID
US6146622A (en) * 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
JP4833414B2 (en) * 1999-05-21 2011-12-07 スリーエム イノベイティブ プロパティズ カンパニー Antimicrobial article
US20070264296A1 (en) 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7959943B2 (en) 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
WO2009152374A2 (en) 2008-06-12 2009-12-17 Medtronic Xomed, Inc. Method for treating chronic wounds
JP2010163397A (en) * 2009-01-16 2010-07-29 Japan Ecologia Co Ltd Antibacterial composition
CN104363904A (en) * 2012-04-20 2015-02-18 亨内平生命科学公司 Compositions for topical treatment of microbial infections
ES2907867T3 (en) 2016-06-20 2022-04-26 Capretto Ehf Stable formulation of antimicrobial lipids
EP3492068A1 (en) * 2017-12-01 2019-06-05 NCP NewCare Products GmbH Composition for treating onychomycosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1772975A (en) 1925-06-20 1930-08-12 Firm C H Boehringer Sohn Chem Process for the production of antiseptic agents
US2190714A (en) 1936-12-01 1940-02-20 Ward Baking Co Process for inhibition of mold
US2154449A (en) 1938-06-15 1939-04-18 Ward Baking Co Process for inhibition of mold
US2466663A (en) 1944-10-20 1949-04-05 Ward Baking Co Fungicide containing caprylic acid and its salt
US2729586A (en) 1952-02-01 1956-01-03 Rystan Company Therapeutic compositions comprising water - soluble chlorophyll and salts of fatty acids
US3404987A (en) 1965-03-31 1968-10-08 Procter & Gamble Food preservative compositions and method for inhibiting microbial growth in food products
FR2097036A1 (en) * 1970-07-29 1972-03-03 Sopharga Lab Lipids contg fatty acids - for treatment of atheroslerosis
US4002775A (en) 1973-07-09 1977-01-11 Kabara Jon J Fatty acids and derivatives of antimicrobial agents
US4489097A (en) 1976-07-28 1984-12-18 The Procter & Gamble Company Intravenous solutions with antimicrobial agent
US4392848A (en) 1979-06-25 1983-07-12 The Procter & Gamble Company Catheterization
US4479795A (en) 1979-06-29 1984-10-30 The Procter & Gamble Company Antimicrobial polymer compositions
US4343788A (en) 1979-06-29 1982-08-10 The Procter & Gamble Company Antimicrobial polymer compositions
US4406884A (en) * 1981-06-23 1983-09-27 The Procter & Gamble Company Topical antimicrobial composition
US4343798A (en) 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4410442A (en) 1982-01-13 1983-10-18 The Procter & Gamble Company Disinfecting solutions for hydrophilic contact lenses
US4474678A (en) * 1982-03-29 1984-10-02 Shell Oil Company Alkanol ethoxylate-containing detergent compositions
US4430381A (en) 1982-06-25 1984-02-07 The Buckeye Cellulose Corporation Monocarboxylic acid antimicrobials in fabrics
DE3338890A1 (en) * 1983-10-27 1985-05-09 Beiersdorf Ag, 2000 Hamburg NEW O / W EMULSIFIERS FOR COSMETIC PURPOSES
NZ211381A (en) * 1984-03-23 1989-04-26 Sterling Drug Inc Antimicrobial surface degerming compositions containing either a bisbiguanide or a bis-(4-(substituted amino)-1-pyridinium)alkane
CA1331559C (en) * 1986-04-21 1994-08-23 Jon Joseph Kabara Antimicrobial preservative compositions and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU692478B2 (en) * 1993-09-14 1998-06-11 Minnesota Mining And Manufacturing Company Disinfectant composition
US5460833A (en) * 1993-09-14 1995-10-24 Minnesota Mining And Manufacturing Company Disinfectant composition
US5490992A (en) * 1993-09-14 1996-02-13 Minnesota Mining And Manufacturing Company Disinfectant composition
WO1995007616A1 (en) * 1993-09-14 1995-03-23 Minnesota Mining And Manufacturing Company Disinfectant composition
EP0676190A2 (en) * 1994-04-07 1995-10-11 Beiersdorf Aktiengesellschaft Composition effective against foot odour containing monoglycerolesters of fatty acids
EP0676190A3 (en) * 1994-04-07 1996-01-24 Beiersdorf Ag Composition effective against foot odour containing monoglycerolesters of fatty acids.
WO1996002228A1 (en) * 1994-07-18 1996-02-01 Minnesota Mining And Manufacturing Company Oral disinfectant for companion animals
EP0704213A1 (en) * 1994-09-29 1996-04-03 Beiersdorf Aktiengesellschaft Dermatologic compositions containing fatty-acid glycerides for the treatment of superinfections
EP0705605A3 (en) * 1994-09-29 1996-05-01 Beiersdorf Ag
EP0709082A3 (en) * 1994-10-28 1998-01-14 Beiersdorf Aktiengesellschaft Combinations of active ingredients based on wool wax acids and glycerides of saturated fatty acids efficient against impure skin, slight forms of acne as well as propionibacterium acnes
EP0709082A2 (en) 1994-10-28 1996-05-01 Beiersdorf Aktiengesellschaft Combinations of active ingredients based on wool wax acids and glycerides of saturated fatty acids efficient against impure skin, slight forms of acne as well as propionibacterium acnes
US5569461A (en) * 1995-02-07 1996-10-29 Minnesota Mining And Manufacturing Company Topical antimicrobial composition and method
US7553871B2 (en) * 1996-02-20 2009-06-30 Gea Westfaliasurge, Inc. Fatty acid antimicrobial
DE19631004A1 (en) * 1996-08-01 1998-02-05 Beiersdorf Ag Deodorizing combinations of active substances based on woollysilicic acids, partial glycerides and aryl compounds
US6749869B1 (en) 1997-09-26 2004-06-15 Ecolab Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection
EP0904693A1 (en) * 1997-09-26 1999-03-31 Ecolab Inc. Pseudoplastic film-forming acidic chlorite composition as teat dip
EP0906724A1 (en) * 1997-09-26 1999-04-07 Ecolab Inc. Pseudoplastic film-forming acidic chlorite composition as teat dip
USRE41279E1 (en) 1997-09-26 2010-04-27 Ecolab Inc. Acidic aqueous chlorite teat dip with improved visual indicator stability, extended shelf life, sanitizing capacity and tissue protection
US6436444B1 (en) 1997-09-26 2002-08-20 Ecolab Inc. Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection
US6699510B2 (en) 1997-09-26 2004-03-02 Ecolab Inc. Acidic aqueous chlorite teat dip with improved visual indicator stability, extended shelf life, sanitizing capacity and tissue protection
US6123966A (en) * 1998-09-03 2000-09-26 Alcide Corporation Stabilized two-part disinfecting system and compositions and methods related thereto
CN100408031C (en) * 1999-02-05 2008-08-06 贝勒研究院 Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
WO2000045649A1 (en) * 1999-02-05 2000-08-10 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US7705048B2 (en) 1999-02-05 2010-04-27 Roe Charles R Method of suppressing the effects of the translocase deficiency of a human infant comprising administration of a seven-carbon fatty acid
US10071070B2 (en) 1999-02-05 2018-09-11 Baylor Research Institute Fatty acid treatment for cardiac patients
US7754764B2 (en) 1999-02-05 2010-07-13 Baylor Research Institute Fatty acid nutritional supplement
US7592370B2 (en) 1999-02-05 2009-09-22 Baylor Research Institute Fatty acid treatment for cardiac patients
US9402822B2 (en) 1999-02-05 2016-08-02 Baylor Research Institute Fatty acid treatment for cardiac patients
US6740679B1 (en) 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
US8507558B2 (en) 1999-02-05 2013-08-13 Baylor Research Institute Fatty acid treatment for cardiac patients
US6310013B1 (en) 1999-10-27 2001-10-30 Ecolab Inc. Lubricant compositions having antimicrobial properties and methods for manufacturing and using lubricant compositions having antimicrobial properties
US6475961B2 (en) 1999-10-27 2002-11-05 Ecolab Inc. Lubricant compositions having antimicrobial properties and methods for manufacturing and using lubricant compositions having antimicrobial properties
AU2002246916B2 (en) * 2000-11-15 2006-06-08 Lavipharm Laboratories, Inc. Bioadhesive cell foam film of sustained-release delivery
US6756051B1 (en) * 2000-11-15 2004-06-29 Li-Lan H. Chen Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same
US6967189B2 (en) 2002-11-27 2005-11-22 Ecolab Inc. Buffered lubricant for conveyor system
US7883732B2 (en) 2003-06-12 2011-02-08 Cargill, Incorporated Antimicrobial salt solutions for cheese processing applications
US7588696B2 (en) 2003-06-12 2009-09-15 Cargill, Incorporated Antimicrobial water softener salt and solutions
US7090882B2 (en) 2003-06-12 2006-08-15 Cargill, Incorporated Antimicrobial salt solutions for food safety applications
US7658959B2 (en) 2003-06-12 2010-02-09 Cargill, Incorporated Antimicrobial salt solutions for food safety applications
CN1878536B (en) * 2003-09-09 2014-11-26 3M创新有限公司 Antimicrobial compositions and methods
US10471036B2 (en) 2003-09-09 2019-11-12 3M Innovative Properties Company Antimicrobial compositions and methods
WO2005023233A3 (en) * 2003-09-09 2005-12-22 3M Innovative Properties Co Antimicrobial compositions and methods
EP3108878A3 (en) * 2003-09-09 2017-03-15 3M Innovative Properties Company Antimicrobial compositions and methods
EP2356982A3 (en) * 2003-09-09 2012-04-04 3M Innovative Properties Co. Antimicrobial compositions and methods
EP2353587A3 (en) * 2003-09-09 2012-04-04 3M Innovative Properties Co. Antimicrobial compositions and methods
CN104398500A (en) * 2003-09-09 2015-03-11 3M创新有限公司 Antimicrobial compositions and methods
US8697748B2 (en) 2004-07-02 2014-04-15 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
US9186344B2 (en) 2004-07-02 2015-11-17 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
US9826770B2 (en) 2005-03-10 2017-11-28 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxycarboxylic acids
WO2006099325A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
US10918618B2 (en) 2005-03-10 2021-02-16 3M Innovative Properties Company Methods of reducing microbial contamination
WO2006099325A3 (en) * 2005-03-10 2007-03-29 3M Innovative Properties Co Methods of treating ear infections
CN101137359B (en) * 2005-03-10 2011-01-12 3M创新有限公司 Methods of treating ear infections
US8486472B2 (en) 2006-01-18 2013-07-16 Cargill, Incorporated Antimicrobial salt solutions for food safety applications
WO2007134055A1 (en) * 2006-05-10 2007-11-22 Medtronic Xomed, Inc. Antibacterial extracellular polysaccharide solvating system
US8623439B2 (en) 2006-05-22 2014-01-07 Cargill, Incorporated Antimicrobial salt solutions for cheese processing applications
US9259006B2 (en) 2008-01-30 2016-02-16 Smartwash Solutions, Llc Antimicrobial compositions and methods of use thereof
WO2009099419A2 (en) * 2008-01-30 2009-08-13 Taylor Fresh Foods, Inc Antimicrobial compositions and methods of use thereof
WO2009099419A3 (en) * 2008-01-30 2010-05-06 Taylor Fresh Foods, Inc Antimicrobial compositions and methods of use thereof
GB2469245B (en) * 2008-01-30 2013-04-24 New Leaf Food Safety Solutions Llc Antimicrobial compositions and methods of use thereof
GB2469245A (en) * 2008-01-30 2010-10-06 Taylor Fresh Foods Inc Antimicrobial compositions and methods of use thereof
US8729049B2 (en) 2009-09-28 2014-05-20 Woresan Gmbh Leaven-based mixture
GB2559173A (en) * 2017-01-30 2018-08-01 Kingston Univ Higher Education Corporation Prophylaxis and treatment of neisseria Gonorrhoeae eye infection
EP3354264A1 (en) * 2017-01-30 2018-08-01 Kingston University Higher Education Corporation Prophylaxis and treatment of neisseria gonorrhoeae eye infection

Also Published As

Publication number Publication date
DE3786481T2 (en) 1993-11-18
DE3752217T2 (en) 1999-05-12
DE3786481D1 (en) 1993-08-19
AU607133B2 (en) 1991-02-28
CA1302280C (en) 1992-06-02
EP0243145A3 (en) 1988-06-22
AU7180387A (en) 1987-10-22
ES2122980T3 (en) 1999-01-01
IE62534B1 (en) 1995-02-08
JPS62267225A (en) 1987-11-19
IE940583L (en) 1987-10-21
JP2543883B2 (en) 1996-10-16
DE3752217D1 (en) 1998-10-15
EP0243145B1 (en) 1993-07-14
EP0243145A2 (en) 1987-10-28
IE870990L (en) 1987-10-21
EP0530861B1 (en) 1998-09-09
EP0530861A3 (en) 1993-04-07
ES2058109T3 (en) 1994-11-01
NZ219973A (en) 1990-05-28

Similar Documents

Publication Publication Date Title
EP0243145B1 (en) Topical antimicrobial pharmaceutical compositions
US5208257A (en) Topical antimicrobial pharmaceutical compositions and methods
US6638978B1 (en) Antimicrobial preservative compositions and methods
US9826770B2 (en) Antimicrobial compositions comprising esters of hydroxycarboxylic acids
EP1673062B1 (en) Antimicrobial compositions and methods
US6110908A (en) Fast acting and persistent topical antiseptic
US4067997A (en) Synergistic microbecidal composition and method
JP2008512392A (en) Disinfectant composition and method of use
CA2969582A1 (en) Cationic antiseptic compositions and methods of use
CA2535004C (en) Topical veterinary compositions and methods for the treatment and prevention of infection
EP0515758A1 (en) Therapeutic use of 1,3-dimethylol-5,5-dimethyl hydantoin
DK175759B1 (en) Topical antimicrobial compositions - contain opt. ethoxylated or propoxylated glyceryl fatty acid ester(s)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AC Divisional application: reference to earlier application

Ref document number: 243145

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): BE CH DE ES FR GB IT LI NL

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): BE CH DE ES FR GB IT LI NL

17P Request for examination filed

Effective date: 19930820

17Q First examination report despatched

Effective date: 19931129

APAB Appeal dossier modified

Free format text: ORIGINAL CODE: EPIDOS NOAPE

APBJ Interlocutory revision of appeal recorded

Free format text: ORIGINAL CODE: EPIDOS IRAPE

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 243145

Country of ref document: EP

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): BE CH DE ES FR GB IT LI NL

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 3752217

Country of ref document: DE

Date of ref document: 19981015

ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: R. A. EGLI & CO. PATENTANWAELTE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2122980

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20040316

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20040422

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20040507

Year of fee payment: 18

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050422

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050430

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20050919

Year of fee payment: 19

BERE Be: lapsed

Owner name: *KABARA JON JOSEPH

Effective date: 20050430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20051101

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20051101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060410

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20060413

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20060419

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060430

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060430

Year of fee payment: 20

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20050422

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20070420

BERE Be: lapsed

Owner name: *KABARA JON JOSEPH

Effective date: 20050430